Most T cell subsets depend on IL-7 for survival. IL-7 binds to IL-7Rα and γc, initiating the signaling cascade. Deletion of IL-7Ra in humans has, for some time, been known to cause severe combined immunodeficiency. More recently, polymorphisms in IL-7R have been shown be a risk factor for a number of diseases that are autoimmune or involve excess immune and inflammatory responses including multiple sclerosis, type 1 diabetes, rheumatoid arthritis, primary biliary cirrhosis, inflammatory bowel disease, atopic dermatitis, inhalation allergy, sarcoidosis and graft-versus host disease. The polymorphism that affects risk to most of these immunopathologies is T244I at the border of the extracellular domain and the transmembrane region. The same region has recently been shown to harbor gain-of-function mutations in acute lymphoblastic leukemia. These studies have suggested new therapies that target the IL-7 pathway. © 2012.
The human IL-7 receptor gene: Deletions, polymorphisms and mutations / R.I. Mazzucchelli, A. Riva, S.K. Durum. - In: SEMINARS IN IMMUNOLOGY. - ISSN 1044-5323. - 24:3(2012 Jun), pp. 225-230. [10.1016/j.smim.2012.02.007]
The human IL-7 receptor gene: Deletions, polymorphisms and mutations
R.I. MazzucchelliPrimo
;A. Riva;
2012
Abstract
Most T cell subsets depend on IL-7 for survival. IL-7 binds to IL-7Rα and γc, initiating the signaling cascade. Deletion of IL-7Ra in humans has, for some time, been known to cause severe combined immunodeficiency. More recently, polymorphisms in IL-7R have been shown be a risk factor for a number of diseases that are autoimmune or involve excess immune and inflammatory responses including multiple sclerosis, type 1 diabetes, rheumatoid arthritis, primary biliary cirrhosis, inflammatory bowel disease, atopic dermatitis, inhalation allergy, sarcoidosis and graft-versus host disease. The polymorphism that affects risk to most of these immunopathologies is T244I at the border of the extracellular domain and the transmembrane region. The same region has recently been shown to harbor gain-of-function mutations in acute lymphoblastic leukemia. These studies have suggested new therapies that target the IL-7 pathway. © 2012.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S104453231200022X-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
291.27 kB
Formato
Adobe PDF
|
291.27 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
nihms360290.pdf
accesso aperto
Tipologia:
Pre-print (manoscritto inviato all'editore)
Licenza:
Non specificato
Dimensione
400.77 kB
Formato
Adobe PDF
|
400.77 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




